Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Cancer Discov. 2016 Dec 16;7(2):156–164. doi: 10.1158/2159-8290.CD-16-0999

Figure 2. BH3 profiling predicts venetoclax sensitivity in primary BPDCNs.

Figure 2

(A) Basal BH3 profiling showing cytochrome c release in response to 100 μM BAD peptide stimulation (normalized to DMSO control) in primary BPDCNs from patients and from PDXs, AMLs, and normal bone marrow (NBM). (B) Basal BH3 profiling in response to 1 μM venetoclax, as in (A). (C) Dynamic BH3 profiling depicting the difference in overall apoptotic priming before and after exposure to 100 nM venetoclax for 4 hours. (D) Correlation of dynamic BH3 profiling delta priming with percent cell death by Annexin V/propidium iodide flow cytometry (Spearman r, and P values for correlation are shown).